BRAF and melanoma: In a phase III trial (CheckMate 037 [20]), 405 patients with advanced melanoma who had progressed after receiving ipilimumab, or ipilimumab and a BRAF inhibitor if they were BRAF V600 mutation-positive, were treated with nivolumab monotherapy or chemotherapy.